Safety
ADVERSE EVENT
Weekly fosaprepitant was well tolerated. There were no significant differences between the weekly and every 3 weeks groups in the proportions of patients who had at least 1 adverse event (grade ≥1) or who had at least 1 serious adverse event (grade ≥3) (